{
    "organizations": [],
    "uuid": "607fcd3c0c97c441c6375aa4e315839e1fc970a0",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/25/business-wire-synergy-pharmaceuticals-to-report-first-quarter-2018-financial-results-and-host-conference-call-and-webcast.html",
    "ord_in_thread": 0,
    "title": "Synergy Pharmaceuticals to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced it intends to release its first quarter 2018 financial results after the NASDAQ market close on Thursday, May 10, 2018. The company will host a conference call and webcast to discuss its financial and business results on the same day at 4:30 p.m. Eastern Time.\nParticipants may access the conference call by dialing 877-407-3978 (US and Canada) or 412-902-0039 (International). Please let the operator know you would like to join the Synergy Pharmaceuticals call.\nTo access the webcast as well as a PDF copy of the presentation, please visit the Investors section of Synergy's website at www.synergypharma.com .\nAn audio replay of the conference call will also be available beginning approximately two hours after the call's conclusion, and will remain available through May 24, 2018. The replay may be accessed by dialing 877-660-6853 (U.S. and Canada) or 201-612-7415 (International) and entering conference ID number 13668774. A replay of the webcast will also be available on the Investors section of Synergy's website at www.synergypharma.com .\nAbout Synergy Pharmaceuticals Inc.\nSynergy is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE ® (plecanatide) and a second product candidate, dolcanatide. please visit www.synergypharma.com .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180425005277/en/\nSynergy Pharmaceuticals Inc.\nGem Hopkins, 212-584-7610\nVP, Investor Relations and Corporate Communications\nghopkins@synergypharma.com\nSource: Synergy Pharmaceuticals Inc.",
    "published": "2018-04-25T16:30:00.000+03:00",
    "crawled": "2018-04-25T16:55:03.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "new",
        "york",
        "business",
        "wire",
        "synergy",
        "pharmaceutical",
        "nasdaq",
        "sgyp",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "novel",
        "gastrointestinal",
        "gi",
        "therapy",
        "today",
        "announced",
        "intends",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "nasdaq",
        "market",
        "close",
        "thursday",
        "may",
        "company",
        "host",
        "conference",
        "call",
        "webcast",
        "discus",
        "financial",
        "business",
        "result",
        "day",
        "eastern",
        "time",
        "participant",
        "may",
        "access",
        "conference",
        "call",
        "dialing",
        "u",
        "canada",
        "international",
        "please",
        "let",
        "operator",
        "know",
        "would",
        "like",
        "join",
        "synergy",
        "pharmaceutical",
        "call",
        "access",
        "webcast",
        "well",
        "pdf",
        "copy",
        "presentation",
        "please",
        "visit",
        "investor",
        "section",
        "synergy",
        "website",
        "audio",
        "replay",
        "conference",
        "call",
        "also",
        "available",
        "beginning",
        "approximately",
        "two",
        "hour",
        "call",
        "conclusion",
        "remain",
        "available",
        "may",
        "replay",
        "may",
        "accessed",
        "dialing",
        "canada",
        "international",
        "entering",
        "conference",
        "id",
        "number",
        "replay",
        "webcast",
        "also",
        "available",
        "investor",
        "section",
        "synergy",
        "website",
        "synergy",
        "pharmaceutical",
        "synergy",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "novel",
        "gi",
        "therapy",
        "company",
        "pioneered",
        "discovery",
        "research",
        "development",
        "effort",
        "analog",
        "uroguanylin",
        "naturally",
        "occurring",
        "endogenous",
        "human",
        "gi",
        "peptide",
        "treatment",
        "gi",
        "disease",
        "disorder",
        "synergy",
        "proprietary",
        "gi",
        "platform",
        "includes",
        "one",
        "commercial",
        "product",
        "trulance",
        "plecanatide",
        "second",
        "product",
        "candidate",
        "dolcanatide",
        "please",
        "visit",
        "view",
        "source",
        "version",
        "http",
        "synergy",
        "pharmaceutical",
        "gem",
        "hopkins",
        "vp",
        "investor",
        "relation",
        "corporate",
        "communication",
        "ghopkins",
        "source",
        "synergy",
        "pharmaceutical",
        "inc"
    ]
}